Trial Profile

A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects With Primary Axillary Hyperhidrosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umeclidinium (Primary)
Indications Hyperhidrosis
Focus Adverse reactions; Pharmacokinetics; Proof of concept
Sponsors GlaxoSmithKline; GSK

Most Recent Events

10 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
05 Jan 2016 Planned end date changed from 1 Mar 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
05 Jan 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com